Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TREMELIMUMAB for Squamous cell carcinoma of head and neck: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 68 adverse event reports in the FDA FAERS database where TREMELIMUMAB was used for Squamous cell carcinoma of head and neck.

Most Reported Side Effects for TREMELIMUMAB

Side Effect Reports % Deaths Hosp.
Pyrexia 178 7.5% 21 143
Diarrhoea 136 5.7% 31 95
Death 116 4.9% 116 17
Colitis 115 4.8% 26 76
Pneumonitis 87 3.6% 44 59
Pneumonia 85 3.6% 36 76
Sepsis 82 3.4% 35 71
Vomiting 78 3.3% 11 70
Febrile neutropenia 72 3.0% 30 60
Malignant neoplasm progression 68 2.9% 22 9
Abdominal pain 64 2.7% 22 60
Dehydration 61 2.6% 21 58
Biliary tract infection 58 2.4% 0 58
Drug-induced liver injury 57 2.4% 11 36
Dyspnoea 57 2.4% 23 32

Other Indications for TREMELIMUMAB

Pancreatic carcinoma (530) Hepatocellular carcinoma (487) Non-small cell lung cancer (448) Pancreatic carcinoma metastatic (142) Small cell lung cancer (80) Bladder transitional cell carcinoma (51) Bladder cancer (44) Non-small cell lung cancer metastatic (44) Neoplasm malignant (42) Product used for unknown indication (25)

Other Drugs Used for Squamous cell carcinoma of head and neck

CETUXIMAB (1,130) NIVOLUMAB (1,124) CISPLATIN (760) PEMBROLIZUMAB (533) FLUOROURACIL (476) CARBOPLATIN (418) PACLITAXEL (305) DOCETAXEL (266) LENVATINIB (183) DURVALUMAB (119)

Related Pages

TREMELIMUMAB Full Profile All Squamous cell carcinoma of head and neck Drugs TREMELIMUMAB Demographics TREMELIMUMAB Timeline